Anika Therapeutics, Inc. (ANIK) Tops Q1 Revenue Tops Views

Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.97, $0.72 better than the analyst estimate of $0.25. Revenue for the quarter came in at $34 million versus the consensus estimate of $16.03 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c